Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us.
about
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesisAntiangiogenic gene therapy of cancer: recent developmentsTetranectin Binds to the Kringle 1-4 Form of Angiostatin and Modifies Its Functional ActivityQuantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimensionMarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?The Contribution of Angiogenesis to the Process of MetastasisProfile of pazopanib and its potential in the treatment of epithelial ovarian cancer3-D visualization and quantitation of microvessels in transparent human colorectal carcinoma [corrected]Multiple Antenatal Dexamethasone Treatment Alters Brain Vessel Differentiation in Newborn Mouse PupsDecreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patientsHydrogels to model 3D in vitro microenvironment of tumor vascularizationActivation of the NF-κB pathway as a mechanism of alcohol enhanced progression and metastasis of human hepatocellular carcinomaFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentCurcumin intake affects miRNA signature in murine melanoma with mmu-miR-205-5p most significantly alteredMicrovascular quantification based on contour-scanning photoacoustic microscopy.Ultrasonic spectrum analysis for in vivo characterization of tumor microstructural changes in the evaluation of tumor response to chemotherapy using diagnostic ultrasound.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapyPreclinical molecular imaging of tumor angiogenesis.Ultrasound assessment of angiogenesis in a matrigel model in ratsModeling of nanotherapeutics delivery based on tumor perfusion.Three-dimensional reconstruction of neovasculature in solid tumors and basement membrane matrix using ex vivo X-ray microcomputed tomographyThree-dimensional analysis of tumour vascular corrosion casts using stereoimaging and micro-computed tomographyPrognostic significance of vascularity in cutaneous melanoma: pilot study using in vivo confocal scanning laser microscopy.In vivo dynamic light scattering microscopy of tumour blood vessels.Comparing contrast-enhanced color flow imaging and pathological measures of breast lesion vascularity.Computerized whole slide quantification shows increased microvascular density in pT2 prostate cancer as compared to normal prostate tissue.Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinibThe effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinomaPhage display peptide probes for imaging early response to bevacizumab treatment.Evaluation of magnetic resonance vessel size imaging by two-photon laser scanning microscopy.Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer.Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics.Cancer models, genomic instability and somatic cellular Darwinian evolutionPredictive model of thrombospondin-1 and vascular endothelial growth factor in breast tumor tissueTargeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply.Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesisCirculating mouse Flk1+/c-Kit+/CD45- cells function as endothelial progenitors cells (EPCs) and stimulate the growth of human tumor xenografts.Breast MR with special focus on DW-MRI and DCE-MRITumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma.Poor prognostic clinicopathologic features correlate with VEGF expression but not with PTEN expression in squamous cell carcinoma of the larynx
P2860
Q24553314-7DA04377-5EBE-4485-8375-E98DCCFE5B8FQ24803786-BA194EB0-9B33-477B-BE95-758D3D3FCA9FQ24804463-8B47007E-52B9-497D-9281-F14BFC1EE713Q24807061-494C07AD-9616-4784-BA03-B12706794F27Q26752752-BEF86288-41CC-4D00-8698-7768A991A714Q26801841-B3FDB572-716C-4031-95C8-87256D4F9A18Q27011840-AD7C989D-B316-4F4A-8037-9291E93FCF1DQ27300839-54C0D675-6B12-42DB-905E-79658C79F904Q27322433-7C63B91F-8B9A-40CA-B210-899B5E21540AQ27853168-E2085257-65E2-418B-9236-24CF85D483E8Q28383786-72791FD2-10F0-400F-8988-E00699DCE90AQ28387441-E65F2DCC-DAEE-4372-95A9-7D8146E2119BQ28533949-BDAC0116-6D01-4403-A099-0D9DDEDA25EEQ28537584-045546EB-C291-4451-9F72-FA627CC2F2CEQ30370851-C6EB541A-870B-46CD-A7F3-B2AF822B59F3Q30452720-6A1382D2-767C-4495-9764-FCA3F3DA3A66Q30455612-B2360F32-502C-429F-AEEC-62AD4A1A1378Q30475818-D8F55F0D-58EC-41C2-A40B-EB48243FC69EQ30503581-46A5F43C-6BCF-4E72-ACAB-743289076945Q30544603-FDA3436F-9049-4CA1-A07E-73CC955EF160Q30588927-E286E4D3-BD19-4BE3-98DB-FA05F3E2EBBDQ30640206-7A2D3FDA-1664-4803-BF66-74F253C61B6CQ33269966-36F39B7C-30E4-4D23-A83C-8216FC7FE435Q33304374-0DE90D0A-BEE5-461D-A52A-E26315B0D639Q33330783-90CE4FF8-876E-424B-AB54-627B56E6A074Q33367977-EB3533F4-DE4C-4262-89E6-F02BEC30466BQ33400232-4A990552-5B2A-40C1-BE0A-A35D91D907BEQ33514437-7C35128A-C88D-4ABE-9A7A-5E117D7016D0Q33541076-86CA5E5B-A40B-4DD9-B875-F1FB35335567Q33550444-22EB4803-8D97-4274-BC2C-ECB5A0FFA571Q33759177-6B5034B9-A84F-4A33-AE6A-5AE36FF0D32EQ33824587-833E9653-29D2-4938-8EEF-12BB4F92586BQ33863476-CB46BDCF-7294-46FB-B90B-F13DBF41DC1FQ33897971-3C3944C9-AD92-4FB7-BB2C-4808CB7BA5D5Q33920350-3759BE65-AEC1-41D5-B166-9B9C4FD03B79Q33942544-2EDAA3BF-598D-44BC-834C-5672D1540976Q33958649-E08C812C-9BB0-4DAC-8DB4-DEA9BD376347Q33965703-2A1418D2-C1E3-453C-9DBE-D0EA1B368F04Q33980073-1933A758-3FBC-43EB-865E-E39D4C9BF189Q33997970-3630E6C4-3979-4359-BD73-5C60952511D3
P2860
Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Clinical application of antian ...... t it does and doesn't tell us.
@ast
Clinical application of antian ...... t it does and doesn't tell us.
@en
Clinical application of antian ...... t it does and doesn't tell us.
@nl
type
label
Clinical application of antian ...... t it does and doesn't tell us.
@ast
Clinical application of antian ...... t it does and doesn't tell us.
@en
Clinical application of antian ...... t it does and doesn't tell us.
@nl
prefLabel
Clinical application of antian ...... t it does and doesn't tell us.
@ast
Clinical application of antian ...... t it does and doesn't tell us.
@en
Clinical application of antian ...... t it does and doesn't tell us.
@nl
P2093
P356
P1476
Clinical application of antian ...... t it does and doesn't tell us.
@en
P2093
Judah Folkman
Lynn Hlatky
Philip Hahnfeldt
P304
P356
10.1093/JNCI/94.12.883
P407
P577
2002-06-01T00:00:00Z